Experts indicate that this rare disorder can lead to various uncomfortable symptoms, including nausea, vomiting, bloating, ...

The US FDA has declined to approve the NDA submitted by Vanda Pharmaceuticals for tradipitant to treat gastroparesis symptoms ...

Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study ...

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesisSOLANA BEACH, Calif., Sept.

Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program.

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Vanda Pharmaceuticals regarding the New Drug Application (NDA) for tradipitant for the treatment of gastroparesis.

Oppenheimer Center for Neurobiology of Stress and Resilience, Clinical Studies and Database Core, Goodman-Luskin Microbiome ...

Gastroparesis is a chronic disabling condition of impaired gastric motility that results in decreased quality of life. Currently available medical therapy consists of prokinetic medication ...